04.04.2016 • NewsElaine BurridgeSun Pharmagenerics

Sun Pharma Buys Novartis Drugs

Indian generic drug maker Sun Pharma has agreed to buy a portfolio of brands from Novartis for $293 million.

The Mumbai-based multi-national is acquiring 14 established prescription brands with combined annualized revenues of around $160 million that address medical conditions across several therapeutic areas.

Under terms of the deal, Novartis will continue to distribute the brands for a certain period, pending transfer of all marketing authorizations to a subsidiary of Sun Pharma which will then hand over marketing and distribution to a “reliable and established” local partner.

Dilip Shanghvi, Sun Pharma’s managing director, said Japan was a market of strategic interest. “This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future,” he commented.

According to December 2015 data from information services provider IMS Health, Japan’s pharmaceutical market is estimated to be worth $73 billion, accounting for more than 7% of the $1 trillion global market.

In separate news, Sun Pharma is partnering with AstraZeneca Pharma India to distribute Type 2 diabetes treatment dapagliflozin in India. AstraZeneca markets the drug as Forxiga, but Sun Pharma will promote and distribute it under the name Oxra.

Under the terms of the deal, both companies will promote, market and distribute dapagliflozin in the country under different brand names.

AstraZeneca will retain intellectual property rights to the therapy. Sun Pharma will also gain rights to promote and distribute the combination of dapagliflozin with metformin under the name Oxramet, following regulatory approval which AstraZeneca India is currently seeking.

Sun Pharma’s CEO, India business, said the agreement further strengthened its partnership with AstraZeneca India and bolstered its diabetes portfolio.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.